© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
Perspective Therapeutics, Inc. (CATX) stock declined over -1.97%, trading at $2.99 on AMEX, down from the previous close of $3.05. The stock opened at $3.02, fluctuating between $2.99 and $3.15 in the recent session.
| Filing Date | Accepted Date | |
|---|---|---|
| Filing Date | Accepted Date | |
|---|---|---|
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Jun 22, 2026 | 3.00 | 3.12 | 2.95 | 3.05 | 2.35M |
| Jun 18, 2026 | 3.02 | 3.13 | 2.93 | 2.95 | 7.66M |
| Jun 17, 2026 | 2.95 | 3.07 | 2.94 | 2.98 | 2.05M |
| Jun 16, 2026 | 2.97 | 3.00 | 2.91 | 2.93 | 765.1K |
| Jun 15, 2026 | 3.00 | 3.13 | 2.87 | 2.94 | 1.76M |
| Jun 12, 2026 | 2.94 | 3.02 | 2.94 | 2.95 | 1.03M |
| Jun 11, 2026 | 3.00 | 3.04 | 2.92 | 2.97 | 1.05M |
| Jun 10, 2026 | 2.98 | 3.06 | 2.91 | 2.95 | 1.14M |
| Jun 09, 2026 | 2.96 | 3.04 | 2.85 | 3.00 | 1.49M |
| Jun 08, 2026 | 3.10 | 3.13 | 2.90 | 2.93 | 1.26M |
| Jun 05, 2026 | 3.25 | 3.29 | 3.01 | 3.03 | 1.86M |
| Jun 04, 2026 | 3.55 | 3.63 | 3.16 | 3.25 | 3.62M |
| Jun 03, 2026 | 3.60 | 3.69 | 3.53 | 3.56 | 969.77K |
| Jun 01, 2026 | 3.91 | 4.06 | 3.65 | 3.66 | 1.45M |
| May 29, 2026 | 4.06 | 4.15 | 3.90 | 3.94 | 892.58K |
| May 28, 2026 | 4.14 | 4.24 | 4.02 | 4.05 | 1.25M |
| May 27, 2026 | 4.16 | 4.34 | 4.12 | 4.16 | 1.03M |
| May 26, 2026 | 4.03 | 4.22 | 3.93 | 4.16 | 1.52M |
| May 22, 2026 | 3.93 | 4.11 | 3.91 | 3.98 | 1.72M |
| May 21, 2026 | 3.70 | 3.97 | 3.66 | 3.87 | 918.02K |
Perspective Therapeutics, Inc., including its various operations, specializes in the comprehensive lifecycle – from development and manufacturing to sales and marketing – of radiopharmaceutical products and medical devices. These advanced solutions are designed to treat cancer and other serious malignant conditions, serving markets both within the United States and globally. A flagship product offered by the company is its CS-1 Cesium-131 brachytherapy seeds. This treatment is specifically utilized for a broad range of cancers, such as those impacting the prostate, brain, lung, head and neck regions, gynecological system, pelvic/abdominal areas, and colorectal tissues. The company distributes its products to medical facilities and physician practices equipped with surgical capabilities. The entity originally operated under the name Isoray, Inc., before officially adopting the name Perspective Therapeutics, Inc. in February 2022. Founded in 1998, the company maintains its corporate headquarters in Richland, Washington.
| Employees | 138 |
| Beta | 1.73 |
| Sales or Revenue | $10.80M |
| 5Y Sales Change% | -0.509% |
| Fiscal Year Ends | June |
| Sector | Healthcare |
| Industry | Medical - Devices |